Eliem Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ELYM Nasdaq 8731 https://eliemtx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eliem Therapeutics Inc

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights - May 11th, 2023 8:10 pm
We're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash Wisely - Apr 21st, 2023 4:00 pm
Top 10 Stocks Activist Investors Are Targeting - Apr 21st, 2023 2:39 pm
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights - Mar 6th, 2023 9:10 pm
Eliem Therapeutics slashing staff amid leadership shakeup - Feb 23rd, 2023 5:38 am
Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce - Feb 10th, 2023 2:31 pm
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition - Feb 9th, 2023 9:01 pm
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference - Nov 30th, 2022 12:00 pm
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights - Nov 14th, 2022 11:10 am
Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth? - Nov 12th, 2022 1:47 pm
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences - Nov 8th, 2022 12:00 pm
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study - Oct 5th, 2022 3:20 pm
Eliem Therapeutics Provides Update on Pipeline Progress - Oct 5th, 2022 11:00 am
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights - Aug 15th, 2022 10:10 am
Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback - Aug 2nd, 2022 11:58 am
Eliem Therapeutics Provides ETX-810 Program Update - Aug 2nd, 2022 11:00 am
Eliem Announces Updated Development Plans For Its Delayed Depression Candidate - Jul 18th, 2022 1:20 pm
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder - Jul 18th, 2022 11:00 am
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022 - Jul 7th, 2022 11:00 am
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP) - Jun 27th, 2022 8:01 pm